Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma

The Lancet Oncology

Volumn 11, Issue 11, 2010, Pages 1014-1016

  Richardson, Paul G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; LENALIDOMIDE; TANESPIMYCIN; THALIDOMIDE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; IMMUNOMODULATION; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NEUROTOXICITY; NOTE; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRAZINES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 78049500513     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70248-5     Document Type: Note

References (8)

1. Broyl A, Corthals SL, Jongen JLM, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010, published online Sept 22. 10.1016/S1470-2045(10)70206-0.
2. Miguel JF San, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917. for the VISTA Trial Investigators.
3. Mateos MV, Richardson PG, Schlag R, et al. Peripheral neuropathy with VMP resolves in the majority of patients and shows a rate plateau. The XII International Myeloma Workshop; Washington, DC, USA; Feb 26-March 1, 2009. 172.
4. Richardson PG, Xie W, Mitsiades CS, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009, 27:3518-3525.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144:895-903.
6. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006, 24:4507-4514.
7. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27:5713-5719.
8. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005, 129:755-762.